Chung S.-D.Huang C.-Y.HONG-JENG YU2021-02-022021-02-0220120028-4793https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864202231&doi=10.1056%2fNEJMc1206002&partnerID=40&md5=039068df1c5d3fb29c542d098abf4c4ehttps://scholars.lib.ntu.edu.tw/handle/123456789/544142[SDGs]SDG3fluorouracil; mitomycin C; antineoplastic agent; antineoplastic agent; bladder cancer; bladder capacity; cancer combination chemotherapy; cancer localization; cancer survival; chemoradiotherapy; clinical effectiveness; drug efficacy; human; letter; local recurrence free survival; muscle invasive bladder cancer; primary tumor; priority journal; quality of life; bladder tumor; female; male; note; bladder cancer; cancer control; cancer prognosis; cancer recurrence; cancer surgery; disease free survival; metastasis; muscle invasive bladder cancer; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Urinary Bladder Neoplasmsletter10.1056/NEJMc1206002228304712-s2.0-84864202231